A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/28/2006	CA2611813A1 New regimens for oral monophasic contraceptives
12/28/2006	CA2611785A1 Use of hif 1alfa modulators for treatment of cancer
12/28/2006	CA2611741A1 Nanoparticulate clopidogrel and aspirin combination formulations
12/28/2006	CA2611712A1 Combretastatin analogs with tubulin binding activity
12/28/2006	CA2611491A1 Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
12/28/2006	CA2611489A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds
12/28/2006	CA2611474A1 Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
12/28/2006	CA2611151A1 Use of sanglifehrin in hcv
12/28/2006	CA2611142A1 Anti-hypercholesterolemic compounds
12/28/2006	CA2610909A1 Manufacturing process for tigecycline
12/28/2006	CA2610890A1 Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
12/28/2006	CA2610829A1 The preparation and use of compounds as aspartyl protease inhibitors
12/28/2006	CA2610828A1 Heterocyclic aspartyl protease inhibitors, preparation and use thereof
12/28/2006	CA2610812A1 Aspartyl protease inhibitors
12/28/2006	CA2610773A1 Clarithromycin or a salt thereof for use in the treatment or prevention of pulmonary disease induced by destruction of pulmonary alveoli
12/28/2006	CA2610742A1 Pyrimidine derivatives for the treatment op gaba b mediated nervous system disorders
12/28/2006	CA2610617A1 The preparation and use of protease inhibitors
12/28/2006	CA2610471A1 Cyclodextrin inclusion complexes and methods of preparing same
12/28/2006	CA2610416A1 Tubulin inhibitor and process for its preparation
12/28/2006	CA2610326A1 Substituted pyrr0lidin-2-0nes , piperidin-2-0nes and isothiazolidine-1, 1-dioxides, their use as kv1.5 potassium channel blockers and pharmaceutical preparations comprising them
12/28/2006	CA2610102A1 New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions
12/28/2006	CA2610093A1 Process for the preparation of sulfonic acid salts of oxabispidines
12/28/2006	CA2610089A1 Process for the preparation of n,n´- disubstituted oxabispidines
12/28/2006	CA2610075A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
12/28/2006	CA2610036A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609994A1 New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
12/28/2006	CA2609993A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609990A1 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609582A1 Aspartyl protease inhibitors
12/28/2006	CA2609562A1 Macrocyclic heterocyclic aspartyl protease inhibitors
12/28/2006	CA2609251A1 Pharmaceutical compositions and use thereof
12/28/2006	CA2608930A1 Pharmaceutical formulations for minimizing drug-drug interactions
12/28/2006	CA2608929A1 Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase
12/28/2006	CA2608821A1 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
12/28/2006	CA2608319A1 Substituted spiro-compounds and the use thereof for producing medicaments
12/28/2006	CA2608314A1 Purine derivatives and their use for treatment of autoimmune diseases
12/28/2006	CA2607600A1 Modified and immediate release memantine bead formulation
12/28/2006	CA2607541A1 Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
12/28/2006	CA2604584A1 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
12/28/2006	CA2598216A1 Androgen receptor modulator compounds and methods
12/28/2006	CA2587189A1 Methods and compositions involving mirna and mirna inhibitor molecules
12/27/2006	EP1736547A1 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation
12/27/2006	EP1736541A1 Novel galectin 9 modification protein and use thereof
12/27/2006	EP1736501A1 Peg-functional nucleic acid conjugate
12/27/2006	EP1736479A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
12/27/2006	EP1736478A1 Methods and compositions for treating flaviviruses and pestiviruses
12/27/2006	EP1736475A1 Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
12/27/2006	EP1736474A1 Piperidine derivative
12/27/2006	EP1736472A1 2-aminopyridine derivative
12/27/2006	EP1736470A2 Pyrimidine derivatives as CB2 cannabinoid receptor modulators
12/27/2006	EP1736469A2 Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol
12/27/2006	EP1736468A2 Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation
12/27/2006	EP1736467A1 Novel sulfonamide derivative
12/27/2006	EP1736466A1 Linear dicationic terphenyls and their aza analogues as antiparasitic agents
12/27/2006	EP1736465A1 Aniline derivatives
12/27/2006	EP1736464A1 Quaternary ammonium compound, process for producing the same, therapeutic agent for cerebrovascular disorder, and therapeutic agent for heart disease
12/27/2006	EP1736173A1 Damaged tissue therapeutic agent and therapeutic method
12/27/2006	EP1736172A1 Method of utilizing organic cation transporter oct3-related molecule for treating mental diseases such as depression, anxiety neurosis, drug addiction and the like
12/27/2006	EP1736167A2 Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use
12/27/2006	EP1736166A2 Extracts from Ajuga reptans cell lines, their preparation and use
12/27/2006	EP1736160A1 Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
12/27/2006	EP1736159A1 Skin conditioning agent
12/27/2006	EP1736158A2 Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts
12/27/2006	EP1736157A1 Anti-itching agent
12/27/2006	EP1736156A1 STABILIZED 4-AMINO-5-CHLORO-N-¬(1R,3r,5S)-8-METHYL-8- AZABICYCLO¬3.2.1\|OCT-3-YL\|-2-¬1-METHYLBUT-2-YNYLOXY\|-BENZAMIDE CONTAINING COMPOSITION
12/27/2006	EP1736155A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
12/27/2006	EP1736154A1 Use of PP-1 inhibitors to prevent missplicing events
12/27/2006	EP1736153A2 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd)
12/27/2006	EP1736152A2 Physiologically stable compositions of butyric acid as well as butyric acid salts and derivatives for treating wounds
12/27/2006	EP1736151A2 Pharmaceutical composition for the therapy of lower urinary tract symptoms
12/27/2006	EP1736150A2 Sertraline salts and sustained-release dosage forms of sertraline
12/27/2006	EP1736149A2 Astaxanthin-containing agent for lowering neutral fat concentration in blood
12/27/2006	EP1736148A1 Medical emulsion of perfluororganic compounds and method for the production thereof
12/27/2006	EP1736147A2 Non-chlorofluorocarbon aerosol formulations
12/27/2006	EP1736146A1 Nicotine transdermal delivery system
12/27/2006	EP1736144A2 Orally disintegrable tablets
12/27/2006	EP1736143A1 Process for producing medicine
12/27/2006	EP1735625A2 New method
12/27/2006	EP1735622A2 Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
12/27/2006	EP1735443A2 RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/27/2006	EP1735442A2 Compositions and methods for treating pancreatic cancer
12/27/2006	EP1735413A1 Compositions containing interestified lipids and phytosterol ester, and related methods, with health and nutrition promoting characteristics
12/27/2006	EP1735337A1 Method of producing highly pure teicoplanin
12/27/2006	EP1735332A1 Azacyclosteroid histamine-3 receptor ligands
12/27/2006	EP1735331A1 D-homo-17-chloro-16(17)en steroids
12/27/2006	EP1735330A1 Progesterone receptor modulators
12/27/2006	EP1735323A1 Synthetic membrane anchors
12/27/2006	EP1735322A1 Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
12/27/2006	EP1735320A1 Compounds and methods for treating dyslipidemia
12/27/2006	EP1735319A1 Inhibitors of histone deacetylase
12/27/2006	EP1735318A2 7h-8,9-dihydro-pyrano(2,3-c)imidazo(1,2a)pyridine derivatives and their use as gastric acid secretion inhibitors
12/27/2006	EP1735315A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
12/27/2006	EP1735314A1 Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
12/27/2006	EP1735313A1 Substituted diaza-spiro-[4.5\|-decane derivatives and their use as neurokinin antagonists
12/27/2006	EP1735312A1 Substituted diaza-spiro-[5.5\|-undecane derivatives and their use as neurokinin antagonists
12/27/2006	EP1735311A1 Beta-carbolines useful for treating inflammatory disease
12/27/2006	EP1735309A1 An improved process for the preparation of n-([1,2,4]triazolopyrimidin-2-yl)aryl sulfonamides
12/27/2006	EP1735308A1 Fused ring azadecalin glucocorticoid receptor modulators
12/27/2006	EP1735307A1 Inhibitors of iap
12/27/2006	EP1735306A2 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof

1 ... 3948 3949 3950 3951 3952 3953 3954 3955 3956 3957 3958 3959 3960 3961 3962 3963 3964 3965 3966 3967 3968 ... 7860